Immunomodulatory mechanisms of lactobacilli by Wells, J.
PROCEEDINGS Open Access
Immunomodulatory mechanisms of lactobacilli
Jerry M Wells
From 10th Symposium on Lactic Acid Bacterium
Egmond aan Zee, the Netherlands. 28 August - 1 September 2011
Abstract
Over the past decade it has become clear that lactobacilli and other probiotic and commensal organisms can
interact with mucosal immune cells or epithelial cells lining the mucosa to modulate specific functions of the
mucosal immune system. The most well understood signalling mechanisms involve the innate pattern recognition
receptors such as Toll-like receptors, nucleotide oligomerization domain-like receptors and C-type lectin receptors.
Binding of microbe-associated molecular patterns with these receptors can activate antigen presenting cells and
modulate their function through the expression of surface receptors, secreted cytokines and chemokines. In vitro
the cytokine response of human peripheral blood mononuclear cells and dendritic cells to lactobacilli can be
strikingly different depending on both the bacterial species and the strain. Several factors have been identified in
lactobacilli that influence the immune response in vitro and in vivo including cell surface carbohydrates, enzymes
modifying the structure of lipoteichoic acids and metabolites. In mice mechanistic studies point to a role for the
homeostatic control of inducible T regulatory cells in the mucosal tissues as one possible immunomodulatory
mechanism. Increasing evidence also suggests that induction of epithelial signalling by intestinal lactobacilli can
modulate barrier functions, defensin production and regulate inflammatory signalling. Other probiotic mechanisms
include modulation of the T cell effector subsets, enhancement of humoral immunity and interactions with the
epithelial-associated dendritic cells and macrophages. A major challenge for the future will be to gain more
knowledge about the interactions occurring between lactobacilli and the host in vivo and to understand the
molecular basis of innate signalling in response to whole bacteria which trigger multiple signalling pathways.
Introduction
The genus Lactobacillus comprises a large heteroge-
neous group of low-G+C Gram-positive, non-sporulat-
ing, and facultative anaerobes [1]. Taxonomically, the
genus Lactobacillus belongs to the phylum Firmicutes,
class Bacilli, order Lactobacillales, family Lactobacilla-
ceae. Currently the genus Lactobacillus contains 154
species of which more than 20 have been sequenced.
They have limited biosynthetic abilities, and require pre-
formed amino acids, B vitamins, purines, pyrimidines
and (usually) a sugar as a carbon and energy source
which is fermented to produce lactic acid as a common
end product. These nutritional requirements restrict
their habitats to those in which the required compounds
are abundant. Nevertheless, the lactobacilli occupy a
variety of niches including milk, plant surfaces, and the
gastrointestinal tract of humans and other animals. Sev-
eral food-associated species of lactobacilli have an excel-
lent safety profile and a “generally-regarded-as-safe”
status in the food industry due to their long history in
food fermentation and human consumption.
Lactobacilli are found in low numbers in the small
intestine of adults but some may originate from fermen-
ted foods or the oral cavity which is home to several
autochthonous species. In adult faeces they form only a
minor component of the microbiota ranging from 0.01
to 0.6% of total counts [2]. In infants lactobacilli are
present in the faeces in variable amounts ranging from
105 to 108 CFU/g with L. salivarius, L. rhamnosus, and
L. paracasei being common species [3]. In addition lac-
tobacilli are dominant members of the human vaginal
microbiota where they play a protective role against uro-
genital infections [4].
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Numerous probiotic studies with different strains of
Lactobacillus have been performed in humans and mur-
ine models to investigate their probiotic potential. While
some clinical studies have been negative or inconclusive
[5-8] others have shown positive results (see e.g. [9-14]).
The lactobacilli have given significant and promising
results in treating acute infectious diarrhoea and in the
prevention of antibiotic-associated diarrhoea in human
clinical trials [10]. The use of probiotic lactobacilli in
the treatment and prevention of allergic diseases and in
the treatment of allergic rhinitis/asthma has been
reviewed recently [15,16]. Most clinical studies on
allergy have been performed with Lactobacillus rhamno-
sus GG (LGG) which was shown to prevent atopic
eczema or dermatitis [13,14]. Subsequent studies on the
use of LGG in the treatment of atopic eczema suggested
a therapeutic effect [9,11,12], whereas more recent stu-
dies show no therapeutic or preventative effects benefits
in the development of sensitization and atopic disease,
particularly in infants with atopic dermatitis [6-8]. These
contrasting results probably reflect the inherent com-
plexity of the allergic syndrome, and differences in the
clinical set-up e.g. different target populations, countries,
intervention schemes and the formulation of LGG used
in the study [15]. Overall there is encouraging evidence
that specific lactobacilli probiotics are valuable in the
prevention and treatment of different diseases but their
successful application would benefit greatly from a bet-
ter understanding of the mechanisms of probiotic action
in clinical studies. The purpose of this review is to dis-
cuss the molecular basis for immune recognition of lac-
tobacilli by the host and to highlight the possible
mechanisms leading to different strain-dependent host
responses. A detailed analysis of results of probiotic stu-
dies in different mouse models and clinical studies is
beyond the scope of this review but the immunomodu-
latory mechanisms of probiotic lactobacilli in vivo are
discussed.
Immune recognition of lactobacilli
Lactobacilli can elicit innate and adaptive immune
responses in the host via binding to pattern recognition
receptors (PRR) expressed on immune cells and many
other tissues including the intestinal epithelium. PRR
recognize conserved molecular structures known as
microbe-associated molecular patterns (MAMPs) and
signal to induce the production of cytokines, chemo-
kines and other innate effectors (recently reviewed
[17-19]). These signalling receptors can be divided into
three families; Toll-like receptors (TLRs), retinoic acid
inducible gene I (RIG-I)-like receptors that recognize
viral RNAs (RLRs) and nucleotide oligomerization
domain-like (NOD) receptors (NLRs). The TLR family
is the best characterized and 10 TLRs have been
identified in humans and 12 in mice [19]. For TLRs it
has been shown that MAMP binding and specificity is
achieved through the arrangement and sequence varia-
tion in the extracellular leucine-rich repeat (LRR)
domains. Dimerization of the TLR and the highly con-
served intracellular Toll-interleukin 1 receptor (TIR)
domains leads to the recruitment of adaptor molecules
such as myeloid differentiation primary response gene
88 (MyD88), toll-interleukin 1 receptor (TIR) domain
containing adaptor protein (TIRAP) and TIR-domain-
containing adapter-inducing interferon-b (TRIF) to initi-
ate the signalling cascade. Each PRR recognizes a speci-
fic molecular pattern and can be expressed on the cell
surface, in intracellular compartments or in the cytosol
(Table 1). TLR1, 2, 4, 5, 6 and 11 recognize mainly
microbial membrane components and are expressed on
the cell surface, TLR3, 7, 8 and 9 recognize nucleic
acids of bacterial and viral origin and are expressed in
intracellular compartments such as the endoplasmic
reticulum, endosomes, lysosomes and endolysosome
(Table 1). In epithelial cells TLR9 is expressed on the
cell surface and intracellularly.
TLR signalling pathways have been reviewed in detail
recently [19] and except for TLR3 involve recruitment
of MyD88, which in turn activates the mitogen-activated
protein kinase (MAPK) pathway and the nuclear factor
B (NF-B) pathway signalling cascades [20] (Fig 1).
TLR3 utilizes the adaptor protein TRIF leading to the
expression of type 1 interferons. In addition this adaptor
serves as an alternative adaptor to MyD88 in the TLR4
signalling pathway. The NOD receptors activate the
MAPK pathway and the canonical NF-B pathway sig-
nalling cascades. In an inactivated state, NF-B is
located in the cytosol as a protein complex with the
inhibitory protein IBa but TLR and NLR signalling
leads to the phosphorylation of IBa, its ubiquitination
and degradation by the cell proteasome. Liberated NF-
B then translocates into the nucleus and induces the
transcription of specific genes (Fig 1).
PRR signalling pathways play a key role in both the
innate and adaptive immune responses, for example by
influencing the skewing of naïve T cells, the regulation
of regulatory T cells and activation of antigen presenting
cells (APCs) such as dendritic cells (DCs) and macro-
phages. DCs are specialized APCs, that regulate both
innate and adaptive immunity (recently reviewed [21])
and are found throughout the lamina propria of the
intestine as well as in the gut-associated lymphoid tis-
sues such as the Peyer’s patches. Most tissue resident
DCs are immature and poorly immunogenic due to the
low expression of MHC molecules and co-stimulatory
molecules. However, contact with MAMPs or other
danger signals induces PRR signalling and activation of
the NF-B pathway leading to maturation and
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activation. Mature DC express high levels of MHC, co-
stimulatory molecules and cytokines required for anti-
gen presentation and T cell activation, clonal expansion
and differentiation [22]. The levels of cytokines pro-
duced by activated DCs are influenced by the nature of
the TLR, CLR and NLR stimuli. This has important
consequences for the induction of different T cell sub-
sets and also our understanding of how different strains
and species of lactobacilli can differentially modulate the
immune response.
In intestinal epithelial cells (IEC), activated NF-B can
induce the production of a broad range of chemokines
and cytokines including interleukins (ILs), tumour
necrosis factors (TNFs), growth factors and inducible
beta-defensins (BDs). These play a key role in maintain-
ing barrier functions and homeostasis (reviewed in [23]).
Endocrine, goblet and enterocytes of the intestinal
epithelium express a range of PRR to sense the presence
of microbes. In the human colon TLR2 and 4 were
shown by immunohistochemical techniques to be
expressed mainly in the enterocytes lining the crypts
[24-26]. In the mouse, immunohistochemical analyses
showed that TLR2, TLR4 and TLR5 are localized on
both the follicle-associated epithelium (FAE) covering
the Peyer’s Patches and the epithelium of the small
intestinal villi and crypts [27] but TLR4 expression was
relatively low. TLR2 is located only on the apical mem-
brane of small intestinal IECs in the mouse and human
[26,27]. In the intestinal epithelium excessive immune
responses to non-pathogens are avoided by several
mechanisms: (i) the regulation of TLR expression, (ii).
TLR localization, (iii) differential apical and basolateral
TLR signalling, (iv) negative feedback regulation of the
NF-kB pathway and (v) the attenuation of NF-B
activation by commensal bacteria. These adaptations are
part of several overlapping and intertwined mechanisms
that maintain homeostasis of inflammatory innate
responses in the gut.
Recognition of lactobacilli via TLR2 signalling pathways
Cell wall components of the lactobacilli can potentially
signal through binding to TLR2 in combination with
TLR6. Over a decade ago bacterial lipoproteins were
shown to recognize TLR2 [28,29]. Recognition is
mediated through binding of the lipid chains which are
post-translationally coupled to a specific N-terminal
lipoprotein signal during secretion [30]. In Gram-posi-
tive bacteria and Gram-negative bacteria a prolipopro-
tein diacylglyceryltransferase (Lgt) transfers a
diacylglyceride group to the cysteine sulfhydryl group
adjacent to the signal peptide cleavage group (Fig 2).
Subsequently the signal peptide is cleaved just before
the cysteine residue resulting in the addition of two acyl
(lipid) chains to the N-terminus of the lipoprotein. The
acyl chains anchor the lipoprotein protein in the cyto-
plasmic membrane. However, in Gram-negative bacteria
and mycobacteria which have an outer membrane an
apolipoprotein N-acyltransferase (Lnt) enzyme attaches
a third acyl group to the amino group of the N-terminal
cysteine. This mediates transport of the lipoprotein to
the outer membrane (Fig 2). Recent crystallographic
structural data on binding of synthetic mimics of the
lipoprotein membrane anchors to TLR1 and 2 or TLR2
and 6 have revealed that the diacyl lipid chains added
by Lgt bind in a hydrophobic pocket in the extracellular
domain of TLR2 (Fig 2). In the case of tri-acylated lio-
poproteins the third lipid chain interacts with a hydro-
phobic channel in TLR1 to promote dimerization and
Table 1 PRR, ligands and subcellular localization
Receptor Localization Ligand Origin of the ligand
TLR2 Cell surface Lipopeptides Bacteria
Lipoproteins G+ bacteria
LTA G+ bacteria
TLR2/1 Cell surface Triacylated lipopeptide G-bacteria, mycoplasma
TLR2/6 Cell surface Diacylated lipopeptides G+ bacteria, mycoplasma
TLR3 Intracellular compartment dsRNA Viruses, virus infected cells
TLR4/MD2 Cell surface, intracellular compartment LPS G- bacteria
TLR5 Cell surface Flagellin protein Bacteria
TLR7 Intracellular compartment ssRNA Viruses
TLR8 Intracellular compartment ssRNA Viruses
TLR9 Intracellular compartment, cell surface DNA DNA viruses, bacteria
TLR11 Cell surface Uropathogenic bacterial components Uropathogenic bacteria
NOD1 Cell cytoplasm Meso-DAP PG from G-, some G+, mycobacterium
NOD2 Cell cytoplasm MDP PG from G-, G+ bacteria, mycobacterium
PG, peptidoglycan; LTA, lipoteichoic acid; LPS, lipopolysaccharide; DAP, diaminopimelic acid; MDP, muramyl dipeptide; G+, Gram positive; G-, Gram negative;
ssRNA, single-stranded RNA; dsRNA, double-stranded RNA.
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Figure 1 Simplified scheme for TLR signaling in enterocytes. TLRs in the cytoplasmic membrane or subcellular compartments such as the
endosome bind the MyD88 adapter protein to initiate signaling. MyD88 recruits TRAF6 and members of the IRAK family (IRAKs) which leads to
activation of the TAK1 complex (TAK1, TAB1/2). The activated TAK complex then activates the IKK complex (IKKa and IKKb) which phosphorylates
the inhibitor of NF-B (IKB) leading to its degradation and the translocation of NF-B (typically p50 and p65 heterodimers) into the nucleus
where it activates gene expression. The activated TAK1 complex simultaneously activates the MAPK pathway resulting in phosphorylation (P) and
activation of the transcription factor AP1. The canonical pathway of NF-B activation and can also be triggered by binding of TRAM and TRIF
adaptor proteins to TLR4 (not shown). The adaptor protein TRIF which binds to TLR3 recruits TRAF3 which interacts with the TBK and IKKi
kinases to promote phosphorylation (P) of IRF3 which translocates to the nucleus and activates transcription of type 1 interferons, especially IFN-
b. The NOD1 and 2 receptros activate NK-B via the serine threonine kinase RICK. This diagram is a modified version of Figure 1 published by
Wells et al., 2010 [17].
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robust signalling [32]. In the case of TLR6 this hydro-
phobic channel is blocked preventing its binding to tri-
acylated lipoproteins. Instead specific interactions with
other parts of the di-acylated lipoprotein promote
dimerization with TLR2 and signalling [31-33]. The co-
receptors CD36, CD14 and lipopolysaccharide binding
protein contribute to the recognition of LTA and TLR2-
mediated signalling [34,35]. The anionic properties of
the WTA and LTA may also contribute to immune sig-
nalling through their binding to scavenger receptors
such as SRA which has been shown to bind purified
LTA [36]. Apart from lipoproteins, TLR2 has been
reported to bind the lipid chains anchoring lipoteichoic
acid (LTA) in the cytoplasmic membrane of Gram-posi-
tive bacteria. In contrast the wall teichoic acids WTA
are covalently attached to the peptidoglycan and pre-
sumably cannot signal through TLR2/6 as they lack a
lipid anchor. LTAs and WTAs are anionic due to a D-
ala substitution by the enzymes of the dlt operon. A
Dlt- mutant of Lactobacillus plantarum strain
NCIMB8826 was found to incorporate much less D-Ala
in its TAs than the WT strain [37]. This defect signifi-
cantly impacted on the immunomodulatory properties
of the bacterium, as shown by a reduction in the secre-
tion of proinflammatory cytokines by peripheral blood
mononuclear cells and monocytes in co-culture with the
dlt mutant and wild type strain [37]. This is also compa-
tible with a study on a minimal synthetic structure of
LTA showing that that the D-ala substitution of the
polyglycerol backbone amplifies the response to the
lipid anchor [38]. Furthermore, the amount of IL-10
produced in co-culture of PBMC with the dlt mutant
was significantly increased compared to the parent
strain [37]. These differences were shown to be TLR2
dependent implicating the interaction of LTA and D-ala
substituted LTA with TLR2 in mediating the different
immune responses. In a mouse model of colitis the Dlt-
mutant was significantly more protective than its WT
counterpart [37]. In contrast a dltD mutation in L.
rhamnosus did not significantly alter cytokine produc-
tion by intestinal epithelial cells and peripheral blood
mononuclear cells in comparison to the wild type strain.
Nevertheless the L. rhamnosus dlt mutant was more
sensitive to anionic detergent, killing by to human beta-
defensin-2 and showed altered cell shape, septation and
increased rate of autolysis [39]. The reason for the dif-
ferences between L. plantarum and L. rhamnosus are
not clear but may be related to the species and strain-
dependent differences in LTA and WTA composition.
For example the cell walls of L. rhamnosus and L. casei
appear to contain only LTA in contrast to other lactoba-
cilli which also contain WTA [39].
Recently deletion of the phosphoglycerol transferase
gene that primes the synthesis of bacterial LTA was
reported in L. acidophilus strain NCK56 resulting in a
strain lacking LTA [40]. Interestingly, the mutant strain
NCK2025 down-regulated production of IL-12 and
TNFa in co-culture with human monocyte derived den-
dritic cells but also significantly enhanced IL-10. The
DC stimulated with the mutant and wild type strain also
differed in their ability to induce proliferation of T cells
isolated from MLN of mice which had been oral fed L.
Figure 2 TLR2 recognition of lipoproteins and LTA. Recognition
of LTA and lipoproteins is mediated through binding of the lipid
chains which anchor these molecules in the membrane. a). All
lipoproteins possess a specific N-terminal lipoprotein signal which
targets the protein for secretion and post-translational modification.
In Gram-positive bacteria and Gram-negative bacteria the Lgt
enzyme transfers a diacylglyceride group to the cysteine sulfhydryl
group adjacent to the signal peptide cleavage site. Subsequently
the signal peptide is cleaved just before the cysteine residue by
LspA yielding a mature di-acylated lipoprotein. However, in Gram-
negative bacteria and mycobacteria the Lnt enzyme attaches a third
acyl group to the amino group of the N-terminal cysteine
promoting its transport to the outer membrane. b). The diacyl lipid
chains added by Lgt bind in a hydrophobic pocket in the
extracellular domain of TLR2 and the head group of the peptide
interacts with TLR6 to promote hetero-dimerization and signalling.
In the case of tri-acylated lipoproteins the third lipid chain interacts
with a hydrophobic channel in TLR1 to promote dimerization and
signalling. This diagram is a modified version of Figure 1 published
by Schenk et al., 2009 [101].
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acidophilus for 4 consecutive days. T-cell proliferation
was significantly abrogated in the LTA mutant-treated
DCs co-cultured with T cells. Adding anti-IL10 antibody
abrogated the suppression of T cell proliferation by the
LTA mutant strain. Thus the T cell suppression was
most likely due to the higher levels of IL-10 produced
by DC cultured with the mutant strain than the wild
type [40]. Furthermore, the NCK205 mutant was super-
ior to the wild type strain in preventing dextran sulphate
sodium (DSS) and colitis in the mouse CD4+CD45RB
high T cell transfer model.
Recognition of lactobacilli genomic DNA via TLR9
Vertebrate innate immune system has evolved specific
mechanisms to recognize bacterial DNA which differs
from vertebrate DNA in respect of the frequency of
methylated cytosin-guanodin dinucleotides (CpG
motifs). In contrast to bacteria CpG motifs occur rarely
in vertebrates and are mostly methylated [41]. TLR9
which is intracellular in immune cells but expressed on
both the apical and basolateral recognizes bacterial CpG
DNA and also synthetic unmethylated CpG oligonucleo-
tide mimics (GpG-ODN) [42]. As the genome of Lacto-
bacillus species differ in their C+G composition the
TLR9 stimulatory capacity of different species is also
likely to be different.
In polarized epithelial cells basolateral TLR9 stimula-
tion with CpG-ODN was shown to activate the NF-B
pathway while apical stimulation prevented NF-B acti-
vation conferring tolerance to chronic TLR challenges
[43]. In vitro treatment of human epithelial cell mono-
layers with various bacterial DNA has been reported to
have differential effects on IL-8 secretion [44]. DNA
from pathogenic species of Salmonella but not from
Lactobacillius, Bifidobacterium and Streptococcus species
present in the VSL3 probiotic mixture induced IL-8
secretion in the human colonic cell line HT29. Further-
more, pre-treatment of HT29 cells with DNA from
VSL3 delayed NF-B activation, stabilized levels of IB
and attenuated IL-8 secretion in response to Salmonella
DNA or TNFa [44]. Similar effects were also recently
reported for HT29 and T84 polarized cell monolayers
using purified DNA from L. rhamnosus GG[45].
CpG DNA and synthetic CpG-ODN stimulate macro-
phages, dendritic cells and monocytes to produce Th1
cytokines and NK cells to produce IFN-g [46,47]. Pro-
longed (6-9 h) pre-exposure of macrophages to CpG
DNA can however attenuate production of the proin-
flammatory cytokine TNFa following subsequent chal-
lenge with LPS via induction of IL-10 expression [48].
In contrast brief pre-exposure (1 – 3 h) of the RAW
264.7 mouse macrophage cell line to CpG-ODN aug-
ments the proinflammatory cytokine response to LPS
[48]. Divergent effects of CpG-ODN have also been
observed in experimental colitis where application of
CpG-ODN in active disease exacerbated inflammation
and prophylactic administration ameliorated colitis
[49,50]. Recent studies in mice suggest that the prophy-
lactic effects are due to the induction of regulatory
properties in T cells [51].
VSL3 probiotic has been shown to reduce mucosal
secretion of TNFa and IFN-g and improve histologic
disease in IL-10 deficient mice (Jijon 2004). This protec-
tive effect appears to be mediated by TLR9-triggered
type I IFN as the addition of neutralizing antibodies
against type I IFN abolished the anti-inflammatory
effects induced by TLR9 agonists, whereas the adminis-
tration of recombinant IFN-b mimicked the anti-inflam-
matory effects induced by TLR9 agonists [52]. The
protective effect of VSL3 was also seen with non-viable
or gamma-irradiated VSL3 probiotic, but not by heat-
killed VSL3. Protection from colitis was seen with VSL3
in TLR2 and TL4 knockout mice but not TLR9 mice
validating the role of TLR9 signaling in the probiotic
mechanism [43].
In summary these studies suggest that unmethylated
DNA fragments containing CpG motifs that are released
from probiotics in vivo have potential to mediate anti-
inflammatory effects via TLR9 signaling at the epithelial
surface. Additionally, bacterial DNA from commensal
microbiota or probiotic bacteria may contribute to the
steady-state homeostasis via the enhancement of regula-
tory mechanisms.
Immune signalling via peptidoglycan
Several studies report that preparations of macromole-
cular PGN (PGNpolymer) can activate NF-B through
human Toll-like receptors 2 (TLR2). However a recent
study showed that purified peptidoglycan (PGN) isolated
from S. aureus mutant lacking prolipoprotein diacylgly-
ceryl transferase (Lgt) which couples the diacyl chains to
lipoproteins in Gram-positive bacteria fails to stimulate
TLR2 signalling [53]. This demonstrates that lipopro-
teins within the macromolecular structures of PGNpoly-
mer, but not PGN itself, activate TLR2. Furthermore, an
extensively purified monomeric PGN (PGNmonomer)
failed to stimulate TLR2 signalling [53].
Peptidoglycan fragments are however recognized by
the NOD1 and NOD2 members of the NLR family of
PRR. There are more than 20 members of this receptor
family in humans and they recognize a wide range of
bacterial ligands and toxins as well as certain damage-
associated molecular patterns (DAMPs) of the host cell
[19,54]. NOD1 and NOD2 are the most well character-
ized NLRs and bind to the synthetic peptidoglycan
mimics meso-diaminopimelic acid (DAP) and muramyl
dipeptide (MDP), respectively [55,56] (Table 1). Both
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receptors are typically expressed in immune cells but in
the intestinal epithelium only NOD1 is expressed
throughout the epithelium. NOD2 expression is predo-
minantly expressed in Paneth cells in the small intestine
[57]. NOD1 and NOD2 activating ligands such muramyl
dipeptide and Tri-peptide mesoDAP are transported
into epithelial cells by the PepT1 di/tripeptide transpor-
ter which is highly expressed in the small intestine. In
the colon PepT1 is poorly expressed but is induced dur-
ing chronic inflammation [58]. NOD1 ligands have also
been shown to enter cells through endocytosis, in a pH
dependent manner [59]. NOD1 and NOD2 can also
detect peptidoglycan fragments produced in the phago-
some or phagolysosome of antigen presenting cells
although the nature of the transporters involved in
translocation to the cytoplasm remains unknown [60].
Typically the unmodified glycan strands of bacterial
peptidoglycan consist of repeating units of b-1,4-linked
N-acetylglucosamine and N-acetylmuramic acid but may
undergo different enzymatic modifications such as O-
acetylation [61]. In several lactobacilli the pentapeptide
chains that are cross-linked between the D-alanine (D-
ala) and L-lysine (D-lys) also differ from the consensus
for lactic acid bacteria (L-ala, D-glu, meso-diaminopime-
lic acid or L-lys, D-ala, D-ala) [62]. For example in L.
casei and L. plantarum the terminal D-ala is replaced by
D-lactate. In addition the D-asparagine that forms the
bridge between the pentapeptides, can be amidated in L.
acidophilus and some other Lactobacillus spp. [62,63].
Highly O-acetylated peptidoglycan might be resistant to
the hydrolytic activity of human lysozyme, thereby
affecting the release of NLR stimulating PGN fragments
and innate immune responses of antigen presenting
cells such as dendritic cells and macrophages.
NOD2 alone does not activate dendritic cells but it
has been shown to act a potent co-stimulator of the
innate immune response exclusively in the presence of
TLR signals [53]. Addition of highly purified PGNmono-
mer isolated from S. aureus in combination with TLR
agonists up-regulated production of IL-12p70 and IL-23
in DC [53]. This synergistic effect was lost in dendritic
cells from NOD2 deficient mice showing that NOD2 is
the bone-fide receptor for highly purified PGN
monomer.
Influence of exopolysaccharides on immune signalling
In addition to PGN and teichoic acids, exopolysacchar-
ides (EPSs) are also commonly associated with the cell
wall of lactobacilli. The EPSs may be attached to the cell
wall or secreted into the milieu. The structural diversity
is large due to the presence of different sugar monomers
and also variation in the modes of linkage, substitution
and branching [64]. Some S-layer proteins of lactobacilli
appear to be glycosylated [65] and other surface proteins
attached to the cell wall may also be glycosylated [66].
EPSs and other cell wall polysaccharides could be recog-
nized by one of several C-type lectin receptors (CLRs)
that are involved in the recognition and capture of anti-
gens by antigen presenting cells such as dendritic cells
and macrophages.
The addition of heat-killed Lactobacillus casei Strain
Shirota or its purified polysaccharide-peptidoglycan (PS-
PG) complex decreased production of IL-6 in LPS-trea-
ted RAW 264.7 cells [67]. A role of the cell wall poly-
saccharide-1 (PS-1) was subsequently confirmed by
Yasuda and colleagues who compared the immune-sup-
pressive properties of PS-1 mutants with the wild type
strain [68]. It is not known whether any lactobacilli
express immunomodulatory zwitterionic polysaccharides
like the prototype PSA found in a non-toxin producing
B. fragilis strain. This PSA is degraded in the phagolyso-
some by oxidative depolymerisation to yield fragments
that can be presented by the MHC class II molecule to
CD4+ T cells carrying ab-T cell receptors [69]. B. fragi-
lis PSA has been shown to influence the special and
temporal development of T cell responses during coloni-
zation of germ-free mice and it can protect against coli-
tis by a mechanism involving the induction of regulatory
T cells and IL-10 production [69].
Some bacterial pathogens such as Mycobacterium
tuberculosis and viral pathogens such as HIV-1 escape
immune surveillance by targeting the C-type lectin DC-
SIGN (DC-specific intercellular adhesion molecule-grab-
bing non-integrin) on dendritic cells. Binding to this
receptor is mediated by high mannose containing carbo-
hydrate structures and affects maturation of DC and
increases expression of IL-10. The result is reduced
capacity of the DC to induce T cell-mediated responses
against the pathogen. DC-SIGN binding activity has also
been described for some strains of Lactobacillus spp.
and is proposed to have an immunomodulatory effect
[70,71].
In vitro assays of immunomodulation by lactobacilli
In vitro co-culture assays with lactobacilli and different
types of immune cells, such as human monocyte derived
DCs, human PBMCs and mouse bone marrow derived
DCs have often been used to assess the immunomodula-
tory potential of different species and strains (reviewed
in [72]). IL-10 production is typically measured because
it is an anti-inflammatory cytokine that suppresses IL-12
production and consequently IFN-g production, thus
favouring a T-helper 2 (Th2) or a regulatory T cell
(Treg) response. In addition, IL-10 down-regulates anti-
gen presentation and inhibits the activation of macro-
phages and thus the production of pro-inflammatory
molecules and chemokines. IL-12 is also commonly
measured as IL-12 production by DC is associated with
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the induction of T-helper 1 (Th1) responses. Further-
more IL-12 elicits IFN-g production by T cells and by
NK cells. There is a lack of evidence linking in vitro
data to in vivo data for different strains but some studies
indicate a correlation. Three studies have shown that the
ability of different lactobacilli to induce a high ratio of
IL-10/IL-12 or IL-10/TNF-a production in immune
cells correlates with their capacity to provide significant
protection in TNBS induced colitis in mice and rats
[73-75]. Foligne et al., showed that the ranking of strains
obtained on the basis of an in vitro IL-10/IL-12 cytokine
induction ratio closely correlates the ranking of the in
vivo ability of the strains to attenuate experimental coli-
tis [73]. In contrast another study has shown that strains
with similar cytokine ratios can have different outcomes
in the mouse DSS model of colitis [76]. The reasons for
their different immunomodulatory properties is not
clear but may be due the levels of cytokines produced
rather than the ratio and/or the survival and persistence
of the strains in vivo.
Several studies have shown that the in vitro cytokine
responses of human PBMC and DC to lactobacilli can
be strikingly different depending on both the species
and the strain [73,77-84]. As discussed further below
different subsets of DC with distinct immunological
phenotypes exist within the mucosal tissues so these in
vitro models serve only as models to characterize the
potential immunomodulatory properties of bacteria and
or other factors (recently reviewed [72]). Despite these
limitations there is evidence that the immune profile
obtained in co-culture assays with bacteria and immune
cells (especially for IL-10 and IL-12) can be predictive of
their in vivo immunomodulatory activities [73,75,85].
Recently Meijerink et al., 2010 studied DC responses
to 42 L. plantarum strains and the amounts of IL-10
induced cytokines ranged from 28 pg/mL to 1095 pg/
mL (39 fold) for IL-10 and from 20-11996 pg/mL (600
fold) for IL-12 (Fig 3) [79]. From a comparison of IL-12
to IL-10 ratios it was clear that these cytokines can vary
independently of each other resulting in strains with dis-
tinct pro-inflammatory and anti-inflammatory profiles.
This remarkable diversity in the immunodulatory prop-
erties of different strains of the same species suggests
that multiple factors can influence the phenotype in
immune assays.
Novel approaches to find immunomodulatory
components of lactobacilli
Comparative genomic analysis is one approach to iden-
tify genetic loci linked to certain phenotypes and has
been applied to Lactobacillus spp. to identify a genes
involved persistence in the intestine [86] and mannose
binding [71]. Similarly, the natural diversity in the
immune response to different strains of L. plantarum
has been exploited to identify novel genes influencing
the dendritic cell response to L. plantarum[79]. In this
study the secreted cytokine amounts or cytokine ratios
for the L. plantarum strains were correlated with the
presence or absence of specific genes by regression
using the Random Forest algorithm. The genotypic data
for each strain was based on comparative hybridisation
to a whole genome microarray of strain WCFS1. This
limited the analysis to genes present in WCFS1 but
nevertheless several interesting loci were identified. The
absence of several plantaricin-related genes correlated
with higher IL-10 production in co-culture with DC. Six
of these genes (lp_0422, lp_0423, lp_0424a, lp_0424,
lp_0425 and lp_0429) were present within the locus
(lp_0403 to lp_0431) required for plantaricin biosynth-
esis and secretion. Deletion mutants of the candidate
genes were constructed in the WCFS1 strain in order to
validate their anticipated effect on cytokine induction.
All but one of the identified genes (a bile salt hydrolase)
affected the immune response as predicted. All of the
IL-12
IL-10 pg/mL IL-12 pg/mL IL-10/ IL-12 ratio
Figure 3 IL-10, IL-12p70 production and the IL-10/IL-12p70 ratio by monocyte-derived dendritic cells stimulated with 20 different L.
plantarum strains. The graphs were produced using data from Meijerink et al., [69] based on one of the 5 representative donors. The different
strains induce striking different amounts of these cytokines. Based on the IL-12 to IL-10 ratios it is clear that these cytokines can vary
independently of each other resulting in strains with distinct pro-inflammatory and anti-inflammatory profiles.
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mutations introduced into the plataracin locus affected
the immune response and were predicted to inhibit
plantaracin production. Thus it is possible that the plan-
taracins directly affect the immune response of DC.
Moreover, the expression of the L. plantarum plantari-
cin immunity protein PlnI is induced in the mouse
intestine, suggesting that bacteriocins are produced in
vivo[87].
Absence of a predicted transcriptional regulator gene
(lp-2991) was also correlated with higher production of
IL-10 and TNFa. A deletion mutant of lp_2991, led to a
significantly higher secretion of IL-10, IL-12p70 and
TNFa compared to the wild-type control. This gene lies
upstream of gtcA3, a putative teichoic acid glycosylation
protein. Upstream of lp_2991 is a manganese transport
gene mntH2 which is orientated in the opposite direc-
tion. Transcriptome analysis and qPCR data supported
the hypothesis that lp_2991 is a repressor of gtcA3 tran-
scription and points to this enzyme as being a prime
candidate for the altered immune response. Interestingly
GtcA3 is predicted to glycosylate TAs including LTA
which is a known TLR2 agonist capable of modulating
immune cell responses. As pointed out above an LTA
mutant and mutants affecting D-ala substitution in LTA
have already been found to have effects on the immune
response [37,40].
An additional approach to identifying new immunomo-
dulatory molecules involves the screening of metage-
nomic clone libraries in high throughput cell-based
screening assays for NF-kB modulation. The develop-
ment of such an assay was recently reported for the func-
tional screening of human gut metagenome libraries [88].
Recently, tools have become available for the automated
analysis of high-content spatio-temporal cellular events
using multi-colour fluorescence microscopy in a high-
throughput fashion. Advances in software capabilities in
the extraction of quantitative measurements from the
acquired images and the management and interpretation
of terabytescale image data allows the combinatorial ana-
lysis of multiple parameters such as fluorescence inten-
sity, distribution and co-localization as well as changes in
cell shape, size or movement in real time [89]. Such an
approach has potential to identify new microbial mole-
cules involved in binding and signalling with host-cells
for example by the use of strain collections or random
and gene-targeted libraries in specific Lactobacillus
strains. Selected small inhibitor RNA (siRNA) knock-
down libraries could also be used in high-throughput
screens to identify host genes leading to specific
responses to bacterial strains or molecules.
Immunomodulatory mechanisms in vivo
Several in vivo studies involving probiotic lactobacilli
point to an immunomodulatory effect on intestinal DCs.
Recently it was shown that administration of several
strains of bacteria (including species of Lactobacillus,
Bifidobacterium and Streptococcus) which had been
selected in vitro to induce high IL-10 to IL-12 ratios
were shown to expand the regulatory T cell population
in the mesenteric lymph nodes [85]. Regulatory T cells
(Tregs) are important in immunological tolerance due
to the suppression of effector T cells at inflammatory
sites and have therapeutic effects in models of inflam-
matory bowel disease, atopic dermatitis and rheumatoid
arthritis. In the mucosa Tregs can be induced in the
mucosal lymphoid tissues by a migratory population of
tolerogenic CD103+ DCs distributed throughout the
lamina propria (LP) of the whole intestine [90] (Fig 4).
This population of DC is distinct from the epithelium-
associated CX3CR1+ DCs and macrophages which
Figure 4 Potential immunomodulatory mechanisms of
probiotic lactobacilli (1). It is not yet clear precisely how oral
administration of certain strains of probiotic lactobacilli can expand
the Treg population in the mesenteric lymph nodes but it may
involve direct activation of lamina propria (LP) CD103+ DC by
MAMPs leading to up-regulation of MHC II and the co-stimulatory
molecules needed for signaling and antigen presentation to naïve T
cells in the lymphoid tissue. (2) Alternatively lactobacilli may be
initially taken up by epithelial-associated CX3CR1+ DCs which could
indirectly lead to maturation of the migratory CD103+ DC
population. The oral administration of probiotic lactobacilli may also
stimulate epithelial signaling and the production of cytokines such
as TGFb and TSLP as well as other factors which imprint a
tolerogenic phenotype on resident CD103+ DC in the LP.
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participate in innate immune clearance and support
inflammatory Th17 T cell responses [91,92]. The tolero-
genic property of the CD103+ CX3CR1- DC subset is
determined by their local tissue environment and in par-
ticular by epithelial derived transforming-growth factor
beta (TGF-b), retinoic acid (RA) and in humans, also
thymic stromal lymphopoietin (TSLP) [93,94]. Interest-
ingly, these factors are induced in IECs after apical
interaction with bacteria in vitro. This suggests that that
luminal contact with bacteria or bacterial factors can
potentially modulate DC function in the LP. The CD103
+ DC also express the enzyme indoleamine 2,3 dioxy-
genase (IDO) which is required for their tolerogenic
function [95]. The immunosuppressive effects of IDO
are linked to its catabolism of tryptophan and and/or
production of immunomodulatory metabolites [95].
Most of our understanding of this tolerogenic mechan-
ism is based on studies in the mouse but the migratory
CD103+ DC subset is also found in the LP and mesen-
teric lymph nodes (MLNs) of humans suggesting the
mechanisms are conserved.
It is not yet clear precisely how oral administration of
lactobacilli can expand the Treg population in the
mesenteric lymph nodes [85] but it may involve activa-
tion of LP DC leading to up-regulation of MHC II and
the co-stimulatory molecules needed for signalling and
antigen presentation to naïve T cells. This effect may be
indirect e.g. by uptake of lactobacilli by the non-migra-
tory DC subset associated with the epithelium (Fig 4).
Another possibility is that oral administration of probio-
tic lactobacilli stimulates epithelial signalling and the
production of cytokines such as TGFb and TSLP as well
as other factors which serve to imprint a tolerogenic
phenotype on resident CD103+ DC in the LP (Fig 4).
A major gap in our knowledge about the mechanisms
of immunomodulation by probiotics (including lactoba-
cilli) concerns their fate in vivo. Studies on the thickness
and physical state of the mucus layer throughout the
intestinal tract has shown that it is thickest in the colon
(~830 μm) and thinnest in the jejunum (~123 μm) [96].
If the mucus is removed by suction, a continuous, firmly
adherent mucus layer remains attached to the epithelial
surface in the colon (~116 μm) but in the small intes-
tine this is much thinner (~20 μm) or absent [96]. The
firm adherent layer of mucus in the colon is relatively
devoid of bacteria [97] showing that the mucus layer is
a significant physical barrier to contact of microbes with
the epithelium. In the small intestine microbial contact
with the epithelium may be more frequent due to the
thinner layer of adherent mucus. Additionally the folli-
cular epithelium covering the mucosal associated lym-
phoid tissue of the Peyer’s Patches (PP) in the small
intestine is considered to be more accessible to antigens
and bacteria present in the luminal compartment.
Evidence that the mucosal tissue responds to orally
consumed lactobacilli comes from recent studies on the
mucosal transcriptome responses to orally consumed L.
plantarum in humans [98,99]. In the study of Baarlen et
al., [99] 3 preparations of L. plantarum were tested in a
double-blind placebo-controlled cross-over design: (i)
the logarithmic-phase of growth, (ii) the stationary-
phase of growth, and (iii) heat-killed ‘‘stationary’’ bac-
teria. The microarray expression profiles of duodenal
biopsies taken 6 h after consumption displayed striking
differences including genes encoding NF-kB subunits
and inhibitors of NF-kB signalling pathways. In a follow
study transcriptomes of proximal small intestine biop-
sies from healthy volunteers were obtained after con-
sumption of three widely used probiotic strains of
different Lactobacillus species (about 1 x 1010 bacteria)
and a placebo control according to a randomized dou-
ble-blind cross-over study design [100]. At 6 h each Lac-
tobacillus strain induced markedly different expression
profiles in the human mucosa, supporting other evi-
dence from in vitro and in vivo studies that the benefi-
cial properties of probiotics are strain dependent.
Notably, there was a large person-to-person variation in
the transcriptome response and a high co-efficient of
variation for some of the chemokine and cytokine effec-
tors which could help to explain the outcomes of pro-
biotics reported in human studies.
Influence of lactobacilli on antibody responses and
immunity
Lactobacilli have been shown to increase the immuno-
genicity of orally administered vaccines such as rotavirus
[101], polio [102], cholera [103] and influenza virus vac-
cine [104]. In the study on cholera vaccination several
probiotic strains were tested for their effect on antibody
responses to the commercial oral cholera vaccine
(Dukoral, SBL Vaccin AB, Stockholm, Sweden). The
probiotic strains were given daily over a 3 week includ-
ing the period in which the oral vaccine was adminis-
tered. Immunoglobulin serum concentrations tended to
increase in most probiotic treated groups and between
day 0 and day 21 significant increases in IgG were
observed for Bifidobacterium lactis B1-04 and Lactoba-
cillus acidophilus La-14 compared to controls (P= 0.01).
However, no effect was observed on the final end point
serum antibody titres to the vaccine or the specific IgA
concentration in saliva [103]. Consumption of LGG or
L. acidophilus CRL431 for five weeks doubled neutrali-
zation titres to an oral polio vaccine given in the fifth
week [102]. In the group consuming probiotics marked
increases in polio-virus specific IgA was also observed
after vaccination. The adjuvant effect of LGG was also
evaluated in conjunction with D x RRV rhesus-human
reassortant live oral rotavirus vaccine in 2-5-month-old
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infants. Infants who received LGG showed an increased
response with regard to rotavirus-specific IgM secreting
cells on day 8 after vaccination. In infants receiving
LGG rotavirus IgM seroconversion was not significantly
different to placebo. However, rotavirus IgA seroconver-
sion was detected in 26/28 (93%) of cases in the LGG
group versus 20/27 (74%) infants given the placebo (p =
0.05) suggesting that LGG has an immunostimulating
effect on oral rotavirus vaccination. Oral consumption
of non-viable Lactobacillus pentosus strain b240
enhanced secretory IgA concentrations in the saliva of
healthy volunteers [105] and more recently this strain
was shown to increase survival time of mice infected
with a lethal dose of influenza virus [104]. The adjuvant
and immunomodulatory effects of lactobacilli on immu-
nity are also evident from many studies utilising lactic
acid bacteria as vaccine delivery vehicles for mucosal
immunization [23,106].
There is also evidence that orally consumed probiotics
can stimulate immune responses to respiratory patho-
gens [107]. Furthermore a recent study on orally con-
sumed LGG as an immune adjuvant for live attenuated
influenza vaccination in healthy adults which showed
significantly improved protective serum responses to
one of the three viruses present in the vaccine [108].
Innate signalling and barrier function
Epithelial cells play a key role in directing the responses
in the gut and maintaining homeostasis via the sensing
of microbes or MAMPs (reviewed in [23]). Commensal
bacteria are not ignored but dynamically controlled via
many complex overlapping and intertwined mechanisms
involving IECs and signals from the microbiota. Inflam-
mation is avoided through the differential signalling and
expression of receptors on the apical and basal mem-
branes of the epithelium and via the regulation of pat-
tern-recognition receptor expression and activity
[17,18,43]. Moreover TLR signalling has been shown to
have a protective role in the intestine [109,110]. Several
lactobacilli have been reported to enhance barrier func-
tion and/or protect against barrier disruption by patho-
gens in vitro (reviewed recently [111,112]). Different
strains of Lactobacillus plantarum have been reported
to prevent the reduction in trans-epithelial resistance
across epithelial monolayers caused by pathogenic E.coli
when co-cultured with the pathogen. This could be due
to inhibition of the pathogen or enhancement of the
barrier function by modulating TJ composition
[113-115]. Lactobacilli have also been reported to
reverse the barrier dysfunction caused by proinflamma-
tory cytokines in vitro[116].
In animal models L. plantarum strains have been
shown to reduce the hyper-permeability associated with
experimental enterocolitis [117] and biliary obstruction
[118]. Recently a study was performed in human volun-
teers which showed that perfusion of L. plantarum into
the duodenum increased the localization (immunofluor-
escent staining) of occludin and ZO-1 in the epithelial
TJs of tissue biopsies [119]. TJ modification was
mediated by TLR2 ligands and conferred protection
against disruption of the TJs by phorbol ester in vitro.
These results are in agreement with recent studies in
mice showing protection from colitis by administration
of TLR2 ligands [109]. The precise signalling mechan-
isms leading to TJ modulation by lactobacilli are not
clear but specific PKC isoforms have been implicated
from in vitro studies with TLR2 agonists [109]. This
does not exclude the involvement of other mechanisms
and receptors in TJ modification by lactobacilli such as
EGF, the ERK1/2 members of the MAPK family
[120-122].
Conclusions
Lactobacilli can elicit innate and adaptive immune
responses in the host is via binding to pattern recogni-
tion receptors (PRR) expressed on immune cells and
many other tissues including the intestinal epithelium.
The di-acylated membrane anchors of lipoproteins and
lipoteichoic acids bind to TLR2 and TLR6 promoting
dimerization and MyD88-mediated activation of the
canonical pathway of NF-kB. The capacity of different
species to stimulate TLR2 signalling varies considerably,
even at the strain level for those species which have
been extensively tested (unpublished Taverne, Meijerink
and Wells). This may reflect differences in the expres-
sion level of certain lipoproteins, their release into the
medium, the amount of LTA and its structure/ modifi-
cation and the effect of shielding factors such as exopo-
lysacchrides. Strain-dependent differences in MAMPs
such as LTA, the peptidoglycan structure and non-
methylated CpG motifs could explain why the in vitro
cytokine responses of human PBMC and DC to lactoba-
cilli can be strikingly different depending on both the
species and the strain. Furthermore, sugars present in
the cell wall and the post-translational modification of
proteins with carbohydrates can also modulate the
immune response by binding to C-type lectin binding
receptors. It seems likely that more new strain-specific
genes and factors that modulate innate recognition by
the host will be discovered using gene-trait matching,
functional metagenomic screens, and high throughput
automated microscopy [79,88].
In vivo lactobacilli have been successfully used to
modulate inflammatory diseases, enhance barrier func-
tions and stimulate immunity. Evidence linking these
beneficial properties to in vitro immune data is sparse
due to the lack of comparative studies with different
strains of probiotics in vitro and in vivo. Nevertheless,
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the immune profile obtained in co-culture assays with
bacteria and immune cells (especially for IL-10 and IL-
12) has been shown to be predictive of their anti-inflam-
matory properties [73,85]. Studies in mice indicate that
certain strains of probiotics can be used prevent or treat
inflammatory diseases via a mechanism which increases
mucosal Treg cells [85]. This most likely involves the
mucosal CD103+ DC that traffic between the lamina
propria and draining lymphoid tissue in humans and
mice. The tolerogenic phenotype of these DC is
imprinted by secreted factors produced by epithelial
cells and other cells and thus may be subject to regula-
tion by epithelial interactions with the luminal micro-
biota. Increasing evidence also suggests that induction
of epithelial signalling by non-pathogenic commensals
in the lumen can modulate barrier functions and regu-
late inflammatory signalling [Karczewski 2010; Neish
2000; Kelly 2004}. Other probiotic mechanisms are likely
to include modulation of the T effector subsets and the
CX3CR1+ LP cells that can sample bacteria through the
epithelium [93]. A major challenge for the future will be
to gain a better understanding of how probiotics can
modulate DC function in the LP and DC in vivo espe-
cially in humans where sampling of immune cells at
mucosal sites is difficult to the invasive nature of the
technique.
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